Although the APOE effect size decreases in older cohorts, the highest AD prevalence is reported in individuals over 80 years of age (Hebert et al., 2003); this indicates that other genes with smaller effect sizes contribute essentially to the disease risk. This evidence concerns the gene APOE and Alzheimer disease.